71.45
Soleno Therapeutics Inc stock is traded at $71.45, with a volume of 4.00M.
It is down -0.75% in the last 24 hours and up +46.35% over the past month.
See More
Previous Close:
$71.99
Open:
$71.54
24h Volume:
4.00M
Relative Volume:
4.64
Market Cap:
$2.30B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-23.84
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
+42.50%
1M Performance:
+46.35%
6M Performance:
+41.51%
1Y Performance:
+66.94%
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SLNO
Soleno Therapeutics Inc
|
71.45 | 2.30B | 0 | -38.99M | -24.94M | -2.9966 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-05-25 | Resumed | Stifel | Buy |
Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
Dec-02-24 | Reiterated | Stifel | Buy |
Sep-03-24 | Initiated | H.C. Wainwright | Buy |
May-10-24 | Initiated | Robert W. Baird | Outperform |
Feb-05-24 | Initiated | Piper Sandler | Overweight |
Jan-23-24 | Initiated | Stifel | Buy |
Nov-21-23 | Resumed | Guggenheim | Buy |
Sep-29-20 | Initiated | Guggenheim | Buy |
Jan-10-20 | Initiated | Craig Hallum | Buy |
Dec-23-19 | Initiated | Oppenheimer | Outperform |
Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Soleno Therapeutics CCO sells shares worth $2.48m - Investing.com
Soleno therapeutics director Matthew Pauls sells $424,797 in stock - Investing.com
Soleno Therapeutics CFO sells $4.88 million in stock - Investing.com
Soleno Therapeutics exec sells shares worth $9.5 million - Investing.com India
Soleno Therapeutics CEO sells $35.3 million in stock - Investing.com
Soleno Therapeutics CEO Anish Bhatnagar sells $35.3m in stock - Investing.com
Soleno Therapeutics Executives Sell Shares - TradingView
Soleno stock price target raised to $100 at H.C. Wainwright - Investing.com
Soleno Therapeutics’ SWOT analysis: FDA approval boosts rare disease stock By Investing.com - Investing.com South Africa
Soleno Therapeutics’ SWOT analysis: FDA approval boosts rare disease stock - Investing.com India
Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment - Markets Insider
Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week? - Insider Monkey
10 Stocks Outperform Broader Market Last Week - Insider Monkey
Soleno Therapeutics (NASDAQ:SLNO) Trading 3.9% Higher on Analyst Upgrade - MarketBeat
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - MSN
Vivo opportunity sells $124 million in Soleno Therapeutics stock By Investing.com - Investing.com South Africa
Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday? - MSN
Guggenheim raises Soleno Therapeutics stock target to $81 By Investing.com - Investing.com Canada
Major Shareholder Sells Massive Stake in Soleno Therapeutics! - TipRanks
Vivo opportunity sells $124 million in Soleno Therapeutics stock - Investing.com
Stifel raises Soleno stock target to $108 after FDA approval By Investing.com - Investing.com South Africa
PANTHERx® Rare Selected by Soleno Therapeutics for the Distribution of VYKAT™ XR - PR Newswire
Stifel raises Soleno stock target to $108 after FDA approval - Investing.com
Soleno Therapeutics price target raised to $108 from $74 at Stifel - TipRanks
FDA Approves First Therapy To Treat Hyperphagia in Prader-Willi Syndrome - Technology Networks
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? - Insider Monkey
Soleno Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
FDA Greenlights Soleno Therapeutics’ VYKAT XR for PWS Hyperphagia - geneonline.com
Oppenheimer lifts Soleno Therapeutics stock target to $105 By Investing.com - Investing.com Canada
Soleno Therapeutics pulls in FDA nod for treatment for rare genetic disease - Mugglehead
Biotech Zooms Into Breakout Zone On Hard-Fought Approval - Investor's Business Daily
First Prader-Willi treatment Vykat XR FDA-approved: Soleno soars - BioWorld MedTech
Drugmaker Soleno Soars on Approval to Treat Never Ending Hunger - Bloomberg.com
Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval (SLNO) - Seeking Alpha
Soleno wins FDA approval for Prader-Willi hyperphagia treatment - Yahoo
Soleno Shares Are Up Today: What's Going On? - Benzinga
FDA Approves Soleno Therapeutics’ Vykat XR for Hyperphagia in Patients with Prader-Willi Syndrome - Pharmaceutical Executive
Baird Raises Soleno Therapeutics' Price Target to $102 From $72, Outperform Rating Maintained - Marketscreener.com
Soleno Therapeutics: A Breakthrough in Rare Disease Treatment - RagingBull
Soleno’s Vykat Gains First Prader-Willi Syndrome Approval, Rivals To Follow - insights.citeline.com
Soleno stock skyrockets on FDA drug approval - Yahoo Finance
Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR - FiercePharma
Soleno jumps as analysts say US nod for rare disease drug transforms treatment options - MSN
Soleno Therapeutics execs reap stock windfall after FDA approves rare disease drugSan Francisco Business Times - The Business Journals
Piper Sandler maintains $93 target on Soleno Therapeutics stock By Investing.com - Investing.com South Africa
Soleno Skyrockets 40% on FDA Nod for VYKAT XR - Wall Street Pit
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - Benzinga
Stifel maintains Soleno Therapeutics buy rating post FDA nod By Investing.com - Investing.com Australia
Behind the Scenes of Soleno Therapeutics's Latest Options Trends - Benzinga
SLNO stock touches 52-week high at $66.16 amid robust growth - Investing.com India
Stifel maintains Soleno Therapeutics buy rating post FDA nod - Investing.com India
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):